PI3K-δ inhibitor for use in treatment regimens
AssigneeiOnctura SA
InventorsCatherine Pickering, Lars Van Der Veen, Michael Lahn, Rebeca Zorrilla, Zoë Johnson
Life of this patent
Estimating the term…
Abstract
A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3Kδ pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea/colitis, respiratory infections, and hematologic toxicities.
Claims14
A method of treating uveal melanoma or mesothelioma in a subject in need thereof, comprising administering to the subject a compound of Formula I wherein the compound of Formula I is
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.